Renaissance Technologies LLC Sells 302,600 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Renaissance Technologies LLC cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 11.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,347,477 shares of the biopharmaceutical company’s stock after selling 302,600 shares during the period. Renaissance Technologies LLC owned approximately 1.92% of Catalyst Pharmaceuticals worth $58,124,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisory Services Network LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Clearstead Advisors LLC raised its position in Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,564 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Monday. The business has a fifty day simple moving average of $31.39 and a two-hundred day simple moving average of $27.33. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).